Notice: Constant automattic\jetpack\extensions\social_previews\FEATURE_NAME already defined in /home2/theprkho/public_html/thepharmatimes.in/wp-content/plugins/jetpack/extensions/blocks/social-previews/social-previews.php on line 14

Deprecated: Function jetpack_form_register_pattern is deprecated since version jetpack-13.4! Use Automattic\Jetpack\Forms\ContactForm\Util::register_pattern instead. in /home2/theprkho/public_html/thepharmatimes.in/wp-includes/functions.php on line 6078
Centre exhorts pharmaceutical companies to invest more in R&D - The Pharma Times | Pharma & Health Care News Portal
Categories: Investment

Centre exhorts pharmaceutical companies to invest more in R&D

New Delhi, June 08,2015: Government on Friday urged pharmaceutical companies to increase investment in research and development (R&D) to emerge as a hub of innovation in low cost health products and services.

India will have to move beyond the manufacturer of generic drugs and emerge as a hub of innovation in low cost health products and services, said Health and Family Welfare Minister JP Nadda at a FICCI conference on ‘India Life Sciences’, a report on life sciences industry.

“Indian manufacturers are spending less than 2% of the total turnover on research and development. The companies need to invest in development of new molecules and innovations,” Nadda said while releasing the ‘Vision Document-2030 of Indian Life Sciences’.

“We are ready to support the suggestions on better R&D. We will discuss the recommendations of the pharmaceutical companies. But we have to see how our R&D can become more robust, innovative and with added inputs,” he said.

Saying that the patents of many biopharmaceuticals and innovative molecules are expiring in 2018, Nadda exhorted on the indigenous companies to grab the opportunity.

“This would be the best time for Indian manufacturers to initiate production of such components so that saving drugs reach millions of patients across the world,” the Union minister said.

The expectation of pharmaceutical industry through ‘Make in India’ is to at least double the production of trade by 2020, he added.

Representatives of pharmaceutical industries requested government to support production of medical devices in the country by making amendments in the Drug and Cosmetic Act, 1940.

“At present, we are importing all the medical equipments used in the hospitals. So the new rules should promote ‘Make in India’ of such devices,” DS Brar, Chairman GVK Biosciences said.

According to Vision Document-2030, the life sciences industry aims to grow to a size of $190-200 billion by the end of this period and also to create four million new jobs in the country over the next 15 years. PTI

The Pharma Times News Bureau

Recent Posts

India’s First Lady Surgeon Trained in Robotic Breast Surgery Performs Karnataka’s 1st Robotic Nipple Sparing Mastectomy

Bengaluru, May 08, 2024: Cancer remains the illness most feared across the globe. But to combat…

11 hours ago

Fortis Hospital, Bannerghatta Road Launches dedicated Parkinson’s Disease and Deep Brain Stimulation Clinic

-  This specialized division empowers patients with neurological disorders to reclaim their mobility through a…

1 week ago

Milestone set in Indian Medical History – SSI Mantra Surgical Robotic System Performs the First-Ever Successful Surgery on One-Year-Old Infant

SSI Mantra Robotic System performs a successful urology procedure on a one-year-old infant with a…

1 week ago

Manipal Hospital Ghaziabad organises Fire Safety Training to Enhance Emergency Response

Ghaziabad, April 22, 2024: In order to strengthen the safety and wellbeing of people, Manipal Hospital…

2 weeks ago

Professor Dr Robert Zeiser receives DKMS Mechtild Harf Science Award 2024

DKMS EMPHASIZES ITS COMMITMENT TO BLOOD CANCER RESEARCH, SUPPORTS YOUNG SCIENTISTS, AND RECOGNIZES OUTSTANDING RESEARCH…

3 weeks ago

Dr. Reddy’s launches drug-free migraine management device Nerivio® in Europe following successful launch in India

Dr. Reddy's has launched Nerivio® in Germany through its step-down subsidiary betapharm To be followed…

3 weeks ago